In tumor cells, interferon gamma (IFN-g-), which responds to an antitumor immune activity, is a major regulator of PD-L1; PD-L1 expression in tumors can also be activated by oncogenic mutations, such as the deletion of phosphatase and tensin homologue in gliomas (38–40). This evidence concerns the gene IFNG and neoplasm.